Issues: Vax Specific

Anthrax

Hepatitis B

Hib

Influenza

Lyme Disease
Meningococcal

MMR    

Polio

Rotavirus

● Smallpox

Tdap/Td

Varicella

Yellow Fever

 

Issues: Misc

Exemptions

Legislation 

New Vax Status

Thimerosal

Independent Vax  Safety Board

 

Vaccine Info

2010 Schedule

ACIP Recs

Components
IOM Reports

● Vax Injury Comp Program
Manufacturer Links

Package Inserts

Reporting AEs

Thimerosal Table

VAERS

VISs

 

Links
 

Search
 

About IVS

Faculty Biographies

Publications

Donations

 

Email IVS

 

Disclaimers & Privacy
 

 

Institute for Vaccine Safety

Johns Hopkins Bloomberg School of Public Health

615 N. Wolfe Street

Room W5041

Baltimore, MD 21205

www.vaccinesafety.edu

 

 

 

 

Components of
Smallpox Vaccine
Excipients Table
Allergens Table
Components Table
 

Indication

Active immunity against vaccinia and smallpox

Proprietary Name

Dryvax

Manufacturer

Wyeth

Viability

Live attenuated

Microorganism

Double-stranded DNA vaccinia virus genus orthopoxvirus

Dose

2 to 3 pressures or punctures

Route

Percutaneous using bifurcated needle

Dose form

Powder for suspension

Appearance

Glossy and cloudy suspension

Concentration

 

Full-strength

108 pock-forming units/mL

Administered dose

2.5 x 105 pock-forming units

Preservatives

Phenol 0.25%

Adjuvant

None

Excipients

Brilliant green diluent until the 1980’s. Since 2002 diluent no longer brilliant green

Allergens

Calf lymph,

Polymyxin B, 100 units/mL

Dihydrostreptomycin, 200 mcg/mL

Chlortetracyclin, 200 mcg/mL

Neomycin, 100 mcg/mL

Media

Skin of vaccinated bovine calves

Packaging

Vial and Diluent for 100 vaccinations

Routine Storage

2 to 8° C

Shipped at 0° C or cooler

updated July 2005

This page was last updated on August 02, 2010

© 2005 Institute for Vaccine Safety